scm logo

The company, which specializes in developing stem cell therapy, was invited to the 2016 MESA Stem Cell Conference held in San Diego from October 5 to 7 and announced the results of research on stem cell therapy. This year, only our company announced it as a Korean company, and Medipost-USA announced it as a Korean company.

The Korea Federation of Regenerative Medicine, which is the organizer of the event and has the highest authority in the field of regenerative medicine, invited only 67 bio-pharmaceutical companies, including us, to event. The invited companies discussed copyright alliances and investment attraction to the world's top multinational pharmaceutical companies and venture investment companies with sales volume.

The company, which was invited for the second time since last year, holds original patents from Korea, the United States, Japan, China, and the European Union (EU) for the manufacturing technology of high-purity stem cell treatments and the "SCM" that can separate high-purity adult stem cells.

The “Subfractionation Culturing Method” developed by the company after long research is a technology that separates high-purity stem cells with much higher purity than the existing stem cell separation method, the " Concentration gradient centrifugation method."

High-purity stem cell therapy using this technology is effective in treating intractable and immune diseases such as GVHD, pancreatitis, and cirrhosis, which are complications caused by immune system rejection after bone marrow transplantation, and Currently, GVHD is single disease in the world and is the disease with the most clinical trials. and its medical importance and commercial potential are high.

Based on this technological innovation, it can be developed as a treatment for various immunological diseases, GVHD such as high purity stem cell therapy, acute pancreatitis, cirrhosis, atopic dermatitis, diabetes, and asthma etc. Based on the high purity stem cell separation technology and treatment manufacturing technology developed so far, the company is pursuing excellence in the field of regenerative medicine to become an internationally recognized leader.

At the event, our CEO Song Sun-uk announced the results of the research process over the past decade, the background of effective stem cell treatment development, and treatment mechanisms according to the identification of immune cell regulation mechanisms of mesenchyma stem cells.

Song Sun-uk, CEO of our company, said, "I am happy to be invited to the world-renowned stem cell conference for two consecutive years and announce the achievements we have made. We will strive to develop high-quality stem cell treatments based on our own high-purity stem cell separation and culture technology, we will also focus on developing treatments that can accurately explain the treatment mechanism, he said.